The frontier AI labs continue releasing models that are better than their predecessors, but there’s an interesting change in how they operate ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

Just one month into 2026, the technology landscape is transforming faster than any prior decade. Corporations across ...

Finding the right book can make a big difference, especially when you’re just starting out or trying to get better. We’ve ...